Orazio Caffo

Summary

Affiliation: S. Maria del Carmine Hospital
Country: Italy

Publications

  1. Hakenberg O, Perez Gracia J, Castellano D, Demkow T, Ali T, Caffo O, et al. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2018;: pubmed publisher
    ..043). Olaratumab + M/P had an acceptable safety profile but did not improve the efficacy of M/P chemotherapy. Further study with selected patient populations and earlier in the disease course might be considered. ..
  2. Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, et al. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. Urol Oncol. 2015;33:265.e15-21 pubmed publisher
    ..The findings of this first study of clinical outcomes in a contemporary series of younger patients with mCRPC showed that their survival is similar to that expected in unselected patients with mCRPC who were of any age. ..
  3. Veccia A, Caffo O, Fellin G, Mussari S, Ziglio F, Maines F, et al. Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study. Radiat Oncol. 2015;10:130 pubmed publisher
    ..5 cc and D10 urethra values of ≤ 210 Gy. The findings of this study show that dosimetric parameters influence only functional QL outcomes while non-functional outcomes are only marginally influenced. ..
  4. Maines F, Caffo O, De Giorgi U, Fratino L, Lo Re G, Zagonel V, et al. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Clin Genitourin Cancer. 2016;14:48-55 pubmed publisher
    ..Our data show that AA is active and safe in very elderly patients and leads to outcomes similar to those observed in younger patients, thus confirming that AA is a manageable therapeutic option for this patient population. ..
  5. Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol. 2015;68:147-53 pubmed publisher
    ..It is debated which sequence of treatments to adopt after docetaxel. Our data do not support the superiority of any of the three new agents in third-line treatment, regardless of the previously administered new agent. ..
  6. Maines F, Caffo O, Veccia A, Trentin C, Tortora G, Galligioni E, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015;96:498-506 pubmed publisher
    ..There was no clear superiority of any one of the three strategies, but a sequence that includes CABA seems to suggest a possible OS advantage. ..
  7. request reprint
    Caffo O, Lunardi A, Trentin C, Maines F, Veccia A, Galligioni E. Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?. Curr Drug Targets. 2016;17:1301-8 pubmed
  8. Caffo O, Thompson C, De Santis M, Kragelj B, Hamstra D, Azria D, et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016;121:193-198 pubmed publisher
    ..Prospective randomized controlled trials are on-going to definitively assess the efficacy of gemcitabine-based chemoradiotherapy for MIBC. ..
  9. Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int. 2008;102:1080-5 pubmed publisher
    ..The patients in arm B had an improvement in pain over time. These data support the existence of a possible advantage in combining docetaxel and EP, which should be verified in a specific randomized phase III study. ..

More Information

Publications10

  1. Maines F, Veccia A, Caffo O. Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?. Eur Urol. 2014;66:179-80 pubmed publisher